…
RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
RenovaCare Inc operates in regenerative medicine and wound care and develops a device-based autologous cell delivery technology intended to treat burns and chronic wounds. Major long-term growth drivers may include wider clinical adoption of cell-based wound therapies, an aging population with rising chronic wound incidence, and successful regulatory progress; investors may find exposure to a niche medical-technology approach worthwhile although public disclosure is limited.
Material investment risks include clinical and regulatory uncertainty, lack of established commercial revenue, frequent need for additional financing, and low liquidity associated with OTC Pink listing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | - | -4.47M | -9.55M | -3.36M | -2.12M |
| Minority interest | - | - | - | - | 0.00M |
| Net income | - | -4.47M | -9.42M | -3.36M | -2.12M |
| Selling general administrative | - | 2.20M | 5.54M | 2.94M | 1.64M |
| Gross profit | - | - | - | - | 0.00M |
| Reconciled depreciation | - | 0.01M | 0.02M | 0.00M | 0.00M |
| Ebit | - | -5.41M | -9.68M | -3.69M | -1.99M |
| Ebitda | - | -5.40M | -9.66M | -3.36M | -1.99M |
| Depreciation and amortization | 0.23M | 0.01M | 0.02M | 0.33M | 0.00M |
| Non operating income net other | - | - | - | - | 0.00M |
| Operating income | - | -5.41M | -9.68M | -3.69M | -2.01M |
| Other operating expenses | - | 5.41M | 9.68M | 3.69M | 2.01M |
| Interest expense | - | 0.01M | 0.13M | 0.33M | 0.14M |
| Interest income | - | 0.01M | 0.13M | 0.33M | 0.02M |
| Net interest income | - | 0.01M | 0.13M | 0.33M | -0.11M |
| Extraordinary items | - | - | - | - | 0.00M |
| Non recurring | - | - | - | - | 0.00M |
| Other items | - | - | - | - | 0.00M |
| Income tax expense | - | -0.01M | -0.13M | -0.33M | 0.02M |
| Total revenue | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | - | 5.41M | 9.68M | 3.69M | 2.01M |
| Cost of revenue | - | - | - | - | 0.00M |
| Total other income expense net | - | 0.94M | 0.13M | 0.33M | -0.06M |
| Discontinued operations | - | - | - | - | 0.00M |
| Net income from continuing ops | - | -4.47M | -9.55M | -3.36M | -2.12M |
| Net income applicable to common shares | - | -4.47M | -9.55M | -3.36M | -2.12M |
| Preferred stock and other adjustments | - | - | - | - | 0.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | - | 3.65M | 8.40M | 12.44M | 15.72M |
| Intangible assets | - | 0.15M | 152854.00M | 0.15M | 152854.00M |
| Other current assets | - | 0.53M | 566275.00M | 102500.00M | 0.17M |
| Total liab | - | 1.31M | 1.32M | 0.28M | 0.39M |
| Total stockholder equity | - | 2.35M | 7.08M | 12.16M | 15.33M |
| Deferred long term liab | - | - | - | - | 0.00M |
| Other current liab | - | 1.04M | 1237437.00M | - | 0.17M |
| Common stock | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | - | -34.24M | -29.77M | -20.22M | -16.86M |
| Other liab | - | - | - | - | 0.00M |
| Good will | - | - | -152853.85M | - | -152853.85M |
| Other assets | - | 0.06M | 0.15M | - | 0.00M |
| Cash | - | 2.85M | 7.41M | 12.19M | 15.40M |
| Total current liabilities | - | 1.31M | 1.29M | 0.28M | 0.39M |
| Current deferred revenue | - | - | -1237437.00M | - | - |
| Net debt | - | -2.82M | -7.33M | -12.19M | -15.40M |
| Short term debt | - | 0.03M | 0.05M | - | 0.00M |
| Short long term debt | - | - | - | - | 0.00M |
| Short long term debt total | - | 0.03M | 0.08M | - | - |
| Other stockholder equity | - | 36.59M | 36.85M | 32.38M | 32.19M |
| Property plant equipment | - | 0.06M | 0.12M | - | 0.00M |
| Total current assets | - | 3.38M | 7.98M | 12.29M | 15.57M |
| Long term investments | - | - | - | - | 0.00M |
| Net tangible assets | - | 2.19M | 6.93M | 12.01M | 15.17M |
| Short term investments | - | - | - | - | 0.00M |
| Net receivables | - | 0.04M | - | - | - |
| Long term debt | - | - | - | - | 0.00M |
| Inventory | - | - | - | - | 0.00M |
| Accounts payable | - | 0.23M | 1.24M | 0.28M | 0.23M |
| Total permanent equity | - | - | - | - | 0.00M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00M |
| Accumulated other comprehensive income | - | - | - | -0.00M | -0.00M |
| Additional paid in capital | - | - | - | - | 0.00M |
| Common stock total equity | - | - | - | - | 0.00M |
| Preferred stock total equity | - | - | - | - | 0.00M |
| Retained earnings total equity | - | - | - | - | 0.00M |
| Treasury stock | - | - | - | - | 0.00M |
| Accumulated amortization | - | - | - | - | 0.00M |
| Non currrent assets other | - | 0.06M | 0.15M | 0.15M | 0.15M |
| Deferred long term asset charges | - | - | - | - | 0.00M |
| Non current assets total | - | 0.27M | 0.42M | 0.15M | 0.15M |
| Capital lease obligations | - | 0.03M | 0.08M | - | 0.00M |
| Long term debt total | - | - | - | - | 0.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | - | 0.00M | -0.05M | 0.00M | 0.00M |
| Change to liabilities | - | 0.04M | 0.96M | 0.06M | 0.06M |
| Total cashflows from investing activities | - | - | -0.05M | -0.05M | -0.05M |
| Net borrowings | - | - | - | - | 0.00M |
| Total cash from financing activities | - | - | - | 0.00M | 14.52M |
| Change to operating activities | - | 0.03M | -0.34M | -0.10M | -0.19M |
| Net income | - | -4.47M | -9.55M | -3.36M | -2.12M |
| Change in cash | - | -4.56M | -4.77M | -3.21M | 12.49M |
| Begin period cash flow | 2.85M | 7.41M | 12.19M | 15.40M | 2.91M |
| End period cash flow | 2.85M | 2.85M | 7.41M | 12.19M | 15.40M |
| Total cash from operating activities | - | -4.56M | -4.72M | -3.21M | -2.03M |
| Depreciation | - | 0.01M | 0.02M | 0.00M | 0.00M |
| Other cashflows from investing activities | - | - | -0.01M | -0.01M | -0.01M |
| Dividends paid | - | - | - | - | 0.00M |
| Change to inventory | - | - | - | - | 0.00M |
| Change to account receivables | - | - | - | - | 0.00M |
| Sale purchase of stock | - | - | - | - | 0.00M |
| Other cashflows from financing activities | - | - | -0.05M | - | 14.52M |
| Change to netincome | - | -0.17M | 4.21M | 0.19M | 0.17M |
| Capital expenditures | 0.00M | 0.00M | 0.04M | 0.04M | 0.04M |
| Change receivables | - | - | - | - | 0.00M |
| Cash flows other operating | - | - | - | - | 0.00M |
| Exchange rate changes | - | - | - | - | 0.00M |
| Cash and cash equivalents changes | - | - | - | - | 0.00M |
| Change in working capital | - | 0.07M | 0.60M | -0.05M | -0.13M |
| Stock based compensation | - | -0.17M | 4.21M | 0.19M | 0.17M |
| Other non cash items | - | 0.00M | - | - | 0.06M |
| Free cash flow | - | -4.56M | -4.76M | -3.21M | -2.03M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| RCAR RenovaCare Inc |
- -% |
0.00 | - | - | - | 5.11 | -1.94 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.
9375 East Shea Blvd, Scottsdale, AZ, United States, 85260
888 398 0202
1
| Name | Title | Year Born |
|---|---|---|
| Mr. Harmel S. Rayat | Pres, CEO, CFO, Interim Sec. & Chairman | 1961 |
| Dr. Robin A. Robinson Ph.D. | Chairman of Scientific Advisory Board, VP & Chief Scientific Officer | 1956 |
| Mr. Justin Frere CPA, CPA, M.B.A., MBA | Treasurer | 1973 |
| Mr. Alan L. Rubino | Consultant | 1955 |
| Dr. Jo Ellen Schweinle M.D. | Chief Medical Officer | NA |
| Mr. Harmel S. Rayat | President, CEO, CFO & Interim Secretary | 1961 |
| Mr. Justin Frere CPA, M.B.A. | Treasurer | 1973 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.